Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure

John A. Schirger, Denise M. Heublein, Horng Haur Chen, Ondrej Lisy, Mlchihisa Jougasaki, Paul W. Wennberg, John C Jr. Burnett

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Objective: To determine whether Dendroaspis natriuretic peptide (DNP), a novel peptide isolated from the venom of the Dendroaspis angusticeps snake that contains a 17-amino acid disulfide ring structure similar to that in atrial, brain, and C-type natriuretic peptides, is present in normal human plasma and myocardium and whether, like the other natriuretic peptides, DNP- like immunoreactivity (DNP-LI) is activated in human congestive heart failure (CHF). Material and Methods: Circulating DNP-LI was assessed in 19 normal human subjects and 19 patients with CHF (New York Heart Association class III or IV) with a specific and sensitive radioimmunoassay for DNP with no cross- reactivity with the other natriuretic peptides. Immunohistochemical studies that used polyclonal rabbit anti-DNP antiserum were performed on human atrial myocardial tissue obtained from four patients with endstage CHF who were undergoing cardiac transplantation and from three donor hearts at the time of transplantation. Results: We report that DNP-LI circulates in normal human plasma and is present in the normal atrial myocardium. In addition, DNP-LI is increased in the plasma of patients with CHF. Conclusion: This study demonstrates, for the first time, the presence of a DNP-like peptide in normal human plasma and in the atrial myocardium. Additionally, these studies demonstrate increased plasma DNP-LI in human CHF. These results support the possible existence of an additional new natriuretic peptide in humans, which may have a role in the neurohumoral activation that characterizes human CHF.

Original languageEnglish (US)
Pages (from-to)126-130
Number of pages5
JournalMayo Clinic Proceedings
Volume74
Issue number2
StatePublished - 1999

Fingerprint

Heart Failure
Natriuretic Peptides
Myocardium
C-Type Natriuretic Peptide
Dendroaspis natriuretic peptide
Elapidae
Peptides
Snakes
Brain Natriuretic Peptide
Venoms
Heart Transplantation
Disulfides
Radioimmunoassay
Immune Sera
Transplantation
Tissue Donors
Rabbits
Amino Acids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. / Schirger, John A.; Heublein, Denise M.; Chen, Horng Haur; Lisy, Ondrej; Jougasaki, Mlchihisa; Wennberg, Paul W.; Burnett, John C Jr.

In: Mayo Clinic Proceedings, Vol. 74, No. 2, 1999, p. 126-130.

Research output: Contribution to journalArticle

Schirger, John A. ; Heublein, Denise M. ; Chen, Horng Haur ; Lisy, Ondrej ; Jougasaki, Mlchihisa ; Wennberg, Paul W. ; Burnett, John C Jr. / Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. In: Mayo Clinic Proceedings. 1999 ; Vol. 74, No. 2. pp. 126-130.
@article{0b0354d189c84cd7914aee947c07fc18,
title = "Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure",
abstract = "Objective: To determine whether Dendroaspis natriuretic peptide (DNP), a novel peptide isolated from the venom of the Dendroaspis angusticeps snake that contains a 17-amino acid disulfide ring structure similar to that in atrial, brain, and C-type natriuretic peptides, is present in normal human plasma and myocardium and whether, like the other natriuretic peptides, DNP- like immunoreactivity (DNP-LI) is activated in human congestive heart failure (CHF). Material and Methods: Circulating DNP-LI was assessed in 19 normal human subjects and 19 patients with CHF (New York Heart Association class III or IV) with a specific and sensitive radioimmunoassay for DNP with no cross- reactivity with the other natriuretic peptides. Immunohistochemical studies that used polyclonal rabbit anti-DNP antiserum were performed on human atrial myocardial tissue obtained from four patients with endstage CHF who were undergoing cardiac transplantation and from three donor hearts at the time of transplantation. Results: We report that DNP-LI circulates in normal human plasma and is present in the normal atrial myocardium. In addition, DNP-LI is increased in the plasma of patients with CHF. Conclusion: This study demonstrates, for the first time, the presence of a DNP-like peptide in normal human plasma and in the atrial myocardium. Additionally, these studies demonstrate increased plasma DNP-LI in human CHF. These results support the possible existence of an additional new natriuretic peptide in humans, which may have a role in the neurohumoral activation that characterizes human CHF.",
author = "Schirger, {John A.} and Heublein, {Denise M.} and Chen, {Horng Haur} and Ondrej Lisy and Mlchihisa Jougasaki and Wennberg, {Paul W.} and Burnett, {John C Jr.}",
year = "1999",
language = "English (US)",
volume = "74",
pages = "126--130",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",

}

TY - JOUR

T1 - Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure

AU - Schirger, John A.

AU - Heublein, Denise M.

AU - Chen, Horng Haur

AU - Lisy, Ondrej

AU - Jougasaki, Mlchihisa

AU - Wennberg, Paul W.

AU - Burnett, John C Jr.

PY - 1999

Y1 - 1999

N2 - Objective: To determine whether Dendroaspis natriuretic peptide (DNP), a novel peptide isolated from the venom of the Dendroaspis angusticeps snake that contains a 17-amino acid disulfide ring structure similar to that in atrial, brain, and C-type natriuretic peptides, is present in normal human plasma and myocardium and whether, like the other natriuretic peptides, DNP- like immunoreactivity (DNP-LI) is activated in human congestive heart failure (CHF). Material and Methods: Circulating DNP-LI was assessed in 19 normal human subjects and 19 patients with CHF (New York Heart Association class III or IV) with a specific and sensitive radioimmunoassay for DNP with no cross- reactivity with the other natriuretic peptides. Immunohistochemical studies that used polyclonal rabbit anti-DNP antiserum were performed on human atrial myocardial tissue obtained from four patients with endstage CHF who were undergoing cardiac transplantation and from three donor hearts at the time of transplantation. Results: We report that DNP-LI circulates in normal human plasma and is present in the normal atrial myocardium. In addition, DNP-LI is increased in the plasma of patients with CHF. Conclusion: This study demonstrates, for the first time, the presence of a DNP-like peptide in normal human plasma and in the atrial myocardium. Additionally, these studies demonstrate increased plasma DNP-LI in human CHF. These results support the possible existence of an additional new natriuretic peptide in humans, which may have a role in the neurohumoral activation that characterizes human CHF.

AB - Objective: To determine whether Dendroaspis natriuretic peptide (DNP), a novel peptide isolated from the venom of the Dendroaspis angusticeps snake that contains a 17-amino acid disulfide ring structure similar to that in atrial, brain, and C-type natriuretic peptides, is present in normal human plasma and myocardium and whether, like the other natriuretic peptides, DNP- like immunoreactivity (DNP-LI) is activated in human congestive heart failure (CHF). Material and Methods: Circulating DNP-LI was assessed in 19 normal human subjects and 19 patients with CHF (New York Heart Association class III or IV) with a specific and sensitive radioimmunoassay for DNP with no cross- reactivity with the other natriuretic peptides. Immunohistochemical studies that used polyclonal rabbit anti-DNP antiserum were performed on human atrial myocardial tissue obtained from four patients with endstage CHF who were undergoing cardiac transplantation and from three donor hearts at the time of transplantation. Results: We report that DNP-LI circulates in normal human plasma and is present in the normal atrial myocardium. In addition, DNP-LI is increased in the plasma of patients with CHF. Conclusion: This study demonstrates, for the first time, the presence of a DNP-like peptide in normal human plasma and in the atrial myocardium. Additionally, these studies demonstrate increased plasma DNP-LI in human CHF. These results support the possible existence of an additional new natriuretic peptide in humans, which may have a role in the neurohumoral activation that characterizes human CHF.

UR - http://www.scopus.com/inward/record.url?scp=0033012808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033012808&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 126

EP - 130

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -